These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3383968)

  • 1. Orosomucoid:prealbumin ratio--a marker of the host-tumor relationship in head and neck cancer.
    Caldani C; Thyss A; Schneider M; Milano G; Buray L; Demard F
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):653-7. PubMed ID: 3383968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.
    Grégoire V; Beauduin M; Humblet Y; Hamoir M; Longueville J; Majois F; Remacle FM; Rousseau F; Salamon E; Wambersie A
    J Clin Oncol; 1991 Aug; 9(8):1385-92. PubMed ID: 2072142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy consisting of cisplatin and continuous infusions of bleomycin and 5-fluorouracil for advanced head and neck cancer. The need for a new stratification for stage IV (M0) disease.
    Recondo G; Cvitkovic E; Azli N; Tellez Bernal E; de Vathaire F; Wibault P; Richard JM; Marandas P; Benahmed M; Domenge C
    Cancer; 1991 Nov; 68(10):2109-19. PubMed ID: 1717121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999.
    Dunphy FR; Dunleavy TL; Harrison BR; Trinkaus KM; Kim HJ; Stack BC; Needles B; Boyd JH
    Cancer; 2001 Mar; 91(5):940-8. PubMed ID: 11251945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.
    Papadimitrakopoulou VA; Dimery IW; Lee JJ; Perez C; Hong WK; Lippman SM
    Cancer J Sci Am; 1997; 3(2):92-9. PubMed ID: 9099459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
    Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
    Fakhry C; Westra WH; Li S; Cmelak A; Ridge JA; Pinto H; Forastiere A; Gillison ML
    J Natl Cancer Inst; 2008 Feb; 100(4):261-9. PubMed ID: 18270337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
    Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
    Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
    Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
    Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
    Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
    Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
    Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
    J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of primary site in assessing chemotherapy response and 7-year survival data in advanced squamous-cell carcinomas of the head and neck treated with initial combination chemotherapy without cisplatin.
    Hill BT; Price LA; MacRae K
    J Clin Oncol; 1986 Sep; 4(9):1340-7. PubMed ID: 3746375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of primary site of stage III and IV squamous cell carcinomas of the head and neck on 7-year survival figures following initial non-cisplatin-containing combination chemotherapy.
    Price LA; Hill BT
    Recent Results Cancer Res; 1986; 103():124-34. PubMed ID: 3526474
    [No Abstract]   [Full Text] [Related]  

  • 14. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck cancer: results of GORTEC Phase II study.
    Fesneau M; Pointreau Y; Chapet S; Martin L; Pommier P; Alfonsi M; Laguerre B; Feham N; Berger C; Garaud P; Calais G
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):154-63. PubMed ID: 19386430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume.
    Chufal KS; Rastogi M; Srivastava M; Pant MC; Bhatt ML; Srivastava K
    Jpn J Clin Oncol; 2006 Sep; 36(9):537-46. PubMed ID: 16905755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the Head and Neck Contracts Program.
    Jacobs C; Makuch R
    J Clin Oncol; 1990 May; 8(5):838-47. PubMed ID: 2185340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma.
    Salas S; Deville JL; Giorgi R; Pignon T; Bagarry D; Barrau K; Zanaret M; Giovanni A; Bourgeois A; Favre R; Duffaud F
    Radiother Oncol; 2008 May; 87(2):195-200. PubMed ID: 18342966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum prealbumin, transferrin and alpha-1-acid glycoprotein in patients with gynecological carcinomas.
    Tosner J; Krejsek J; Louda B
    Neoplasma; 1988; 35(4):403-11. PubMed ID: 3141823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.